PMID- 34210500
OWN - NLM
STAT- MEDLINE
DCOM- 20210715
LR  - 20210715
IS  - 2666-6367 (Electronic)
IS  - 2666-6367 (Linking)
VI  - 27
IP  - 7
DP  - 2021 Jul
TI  - Guidelines for the Prevention and Management of Graft-versus-Host Disease after 
      Cord Blood Transplantation.
PG  - 540-544
LID - S2666-6367(21)00755-7 [pii]
LID - 10.1016/j.jtct.2021.03.012 [doi]
AB  - The incidence of graft-versus-host disease (GVHD) after cord blood (CB) 
      transplantation (CBT) is lower than expected given the marked degree of human 
      leukocyte antigen (HLA)-mismatch of CB grafts. While the exact mechanism that 
      underlies this biology remains unclear, it is hypothesized to be due to the low 
      number of mostly immature T-cells infused as part of the graft1,2, and increased 
      tolerance of CB-derived lymphocytes induced by the state of pregnancy. 
      Nevertheless, acute GVHD (aGVHD) is a significant complication of CBT. In 
      contrast, the incidence of chronic GVHD (cGVHD) following CBT is lower than what 
      is observed following matched related or unrelated donor HSC transplantation 
      (HSCT)3-6. This review outlines the guidelines for the prevention and management 
      of acute and chronic GVHD following CBT.
CI  - Copyright (c) 2021 The American Society for Transplantation and Cellular Therapy. 
      Published by Elsevier Inc. All rights reserved.
FAU - Ponce, Doris M
AU  - Ponce DM
AD  - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan 
      Kettering Cancer Center, New York, New York; Weill Cornell Medical College; New 
      York, New York. Electronic address: ponced@mskcc.org.
FAU - Politikos, Ioannis
AU  - Politikos I
AD  - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan 
      Kettering Cancer Center, New York, New York; Weill Cornell Medical College; New 
      York, New York.
FAU - Alousi, Amin
AU  - Alousi A
AD  - Stem Cell Transplantation and Cellular Therapy, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas.
FAU - Carpenter, Paul A
AU  - Carpenter PA
AD  - Fred Hutchinson Cancer Research Center, Division of Clinical Research, Department 
      of Pediatrics, Seattle, Washington.
FAU - Milano, Filippo
AU  - Milano F
AD  - Fred Hutchinson Cancer Research Center, Department of Oncology, Seattle, 
      Washington.
FAU - MacMillan, Margaret L
AU  - MacMillan ML
AD  - Blood and Marrow Transplantation & Cellular Therapy Program, Department of 
      Pediatrics, University of Minnesota, Minneapolis, Minnesota.
FAU - Barker, Juliet N
AU  - Barker JN
AD  - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan 
      Kettering Cancer Center, New York, New York; Weill Cornell Medical College; New 
      York, New York.
FAU - Horwitz, Mitchell E
AU  - Horwitz ME
AD  - Hematologic Malignancies and Cellular Therapies, Department of Medicine, Duke 
      Cancer Institute, Durham, North Carolina.
CN  - American Society for Transplantation and Cellular Therapy Cord Blood Special 
      Interest Group
LA  - eng
PT  - Practice Guideline
PT  - Review
PL  - United States
TA  - Transplant Cell Ther
JT  - Transplantation and cellular therapy
JID - 101774629
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Cord Blood Stem Cell Transplantation/adverse effects
MH  - *Graft vs Host Disease/prevention & control
MH  - HLA Antigens
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Unrelated Donors
OTO - NOTNLM
OT  - Cord blood transplant
OT  - Graft-versus-host disease
EDAT- 2021/07/03 06:00
MHDA- 2021/07/16 06:00
CRDT- 2021/07/02 05:43
PHST- 2021/03/05 00:00 [received]
PHST- 2021/03/07 00:00 [accepted]
PHST- 2021/07/02 05:43 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/16 06:00 [medline]
AID - S2666-6367(21)00755-7 [pii]
AID - 10.1016/j.jtct.2021.03.012 [doi]
PST - ppublish
SO  - Transplant Cell Ther. 2021 Jul;27(7):540-544. doi: 10.1016/j.jtct.2021.03.012.